Prolactin levels in menopausal women on long-term estrogen implants.
Prolactin levels were measured in 71 menopausal women before treatment and 32 treated with steroid implants. In neither group was there any case of hyperprolactinemia. Although prolactin levels were on average 13% higher in the women who had had long-term treatment with the implants, they were, nevertheless, not significantly different from the corresponding levels in the pretreated group. Treatment with steroid implants at the dose and duration studied therefore did not significantly increase the risk of hyperprolactinemia occurring in treated as compared with pretreated menopausal women.
Goh
H H
HH
Department of Obstetrics and Gynecology, National University Hospital, Singapore.
McCarthy
T G
TG
Dramusic
V
V
Ratnam
S S
SS
D000328:Adult; D004343:Drug Implants; D004958:Estradiol / Q000097:blood; D004967:Estrogens / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008593:Menopause; D008594:Menopause, Premature / Q000097:blood* / Q000187:drug effects; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use; D011388:Prolactin / Q000097:blood*
D004343:Drug Implants; D004967:Estrogens; D004958:Estradiol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D009640:Norethindrone